GTPase inhibitors and methods of use
The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.
1. A pharmaceutical composition comprising N6-(2-((4-(diethylamino)-1-methylbutyl)amino)-6-methyl-4-pyrimidinyl)-2-methyl-4,6-quinolinediamine and a pharmaceutically-acceptable carrier.
2. The pharmaceutical composition according to claim 1 , wherein N6-(2-((4-(diethylamino)-1-methylbutyl)amino)-6-methyl-4-pyrimidinyl)-2-methyl-4,6-quinolinediamine compound is at least 1% by weight.
3. The pharmaceutical composition according to claim 1 further comprising a second pharmaceutically active agent in addition to N6-(2-((4-(diethylamino)-1-methylbutyl)amino)-6-methyl-4-pyrimidinyl)-2-methyl-4,6-quinolinediamine.
4. The pharmaceutical composition according to claim 3 , wherein the second pharmaceutically active agent is selected from the group consisting of farnesyl protein transferase inhibitors, prenyl-protein transferase inhibitors, geranylgeranyl-protein transferase inhibitors, toxins and combinations thereof.